Evolus outlines $700M 2028 revenue target and cost realignment amid market softness
Source: SeekingAlpha
2025-08-05 19:16:27 ET
More on Evolus
- Evolus, Inc. (EOLS) Q2 2025 Earnings Call Transcript
- Evolus, Inc. 2025 Q2 - Results - Earnings Call Presentation
- Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings
- Evolus GAAP EPS of -$0.27 misses by $0.07, revenue of $69.4M misses by $12.64M
- Seeking Alpha’s Quant Rating on Evolus
Read the full article on Seeking Alpha
For further details see:
Evolus outlines $700M 2028 revenue target and cost realignment amid market softness
Evolus Inc.
NASDAQ: EOLS
EOLS Trading
0.86% G/L:
$5.285 Last:
161,989 Volume:
$5.28 Open:
EOLS Latest News
EOLS Stock Data
$288,448,039
43,258,131
1.1%
49
N/A
Pharmaceuticals
Healthcare
US
Newport Beach
